The therapeutic application of Gyno-Daktarin, containing Miconazole Nitrate, is relevant in clinical settings that involve acute or unstable symptom patterns, applied across domains where additional symptomatic support is needed.

Addressing Vulvovaginal Candidiasis and Fungal Infections

This medication is generally used in clinical settings to help treat vulvovaginal candidiasis or vaginal thrush, which is caused by susceptible fungal organisms. Its main use is in situations involving certain distressing symptoms linked to this condition. The medicine supports management of the condition, which is relevant in contexts involving heightened systemic burden.

Indications for use generally include conditions characterized by episodic or fluctuating manifestations, such as acute thrush, recurrent episodes, and concurrent mycotic infection in the male sexual partner. It is commonly used across conditions presenting with acute episodes and in situations where symptoms may intensify temporarily.

Relief of Acute Irritation, Pruritus, and Burning

A relevant therapeutic benefit is the supportive management of symptoms related to inflammatory or irritative states that accompany the infection. Gyno-Daktarin is applied in scenarios where additional management of discomfort is required, addressing symptoms such as itching (pruritus), burning sensations, and local inflammation (redness and swelling). The symptomatic relief offers support that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

---

Quick Fact: Symptom Support in Vulvovaginal Conditions
Primary Symptom Management	Itching and local burning sensations
Key Therapeutic Goal	Used for managing symptoms related to inflammatory or irritative states
Clinical Relevance	Applied across acute and recurrent episodes of thrush

Regulatory References

1. NIH MedlinePlus overview on Miconazole Vaginal

The eligibility for using Miconazole Nitrate vaginal preparations (Гино-Дактарин) is strictly defined by regulatory documents based on patient population and specific health criteria.

Eligibility Scope

Criteria	Official Regulatory Status
Allowed Population	Adults with vulvovaginal candidiasis.
Contraindicated	Known hypersensitivity to Miconazole Nitrate or other azole antifungal agents.

Age- and Condition-Based Rules

Classification	Eligibility Rule (As Stated in Label)
Pediatric Use	Not recommended for use in children under 12 years of age. Prescribing information in some regions may advise against use under 18 years [Source: FDA, SmPC Equivalent].
Pregnancy	Prohibited during the first trimester unless use is considered essential by a physician; caution is advised for use during lactation [Source: DailyMed].
Systemic Conditions	Patients with diabetes or a weakened immune system (e.g., HIV/AIDS) must consult a doctor before use to rule out a more serious underlying cause [Source: FDA Access Data].
Restrictions	Use is restricted if relying on latex condoms or diaphragms, as the formulation may compromise their efficacy [Source: DailyMed].

The official profile establishes absolute prohibitions, such as known drug sensitivity, and mandates conditional eligibility for patients with systemic conditions or those who are pregnant. These eligibility classifications strictly regulate the permitted user base according to government-approved standards.

Interactions with other medicines and products

The regulatory profile for Miconazole Nitrate (Гино-Дактарин) details specific interaction patterns primarily related to its effect on the body's metabolic pathways. Even with minimal systemic absorption from the vaginal route, the medicine may inhibit the enzymes CYP2C9 and CYP3A4, potentially reducing the clearance and increasing the systemic concentration of other co-administered medicinal products.

Documented Pharmacokinetic Interactions

This pharmacokinetic mechanism leads to several important regulatory classifications. The co-administration of Miconazole with certain narrow therapeutic index drugs, such as Pimozide and Ergot Alkaloids (e.g., Dihydroergotamine), is considered contraindicated due to the risk of severe concentration increases. Furthermore, the combination with Oral Anticoagulants (like Warfarin) can dangerously elevate the International Normalized Ratio (INR), which increases the documented risk of bleeding. Miconazole also increases the systemic exposure of certain Statins (e.g., Simvastatin) and may alter hormone levels from some Oral Contraceptives.

Local Product and Physical Restrictions

Separately, the use of the product involves local constraints. Miconazole should not be used concurrently with other local vaginal products, including tampons, douches, or spermicides. Additionally, reliance on latex products such as condoms or diaphragms is restricted during treatment because the formulation base may compromise the physical integrity of the rubber, leading to functional failure.

The action of Miconazole Nitrate involves a dual-mechanism pathway that results in the inactivation and structural degradation of susceptible fungal organisms at the cellular level.

Inhibition of Fungal Cell Membrane Structure

This core mechanism involves the progressive disruption of the fungal cell membrane's integrity. The active molecule acts as a non-competitive inhibitor of lanosterol 14alpha-demethylase, a vital enzyme in the fungus. By blocking this enzyme, the synthesis of the essential membrane sterol, ergosterol, is halted. This failure causes the accumulation of toxic intermediate sterols that physically destabilize the membrane and consequently rupture the fungal cell (cell lysis).

Internal Cellular Toxicity and Morphogenesis Control

A secondary mechanism involves Miconazole's ability to inhibit fungal oxidases and peroxidases, enzymes required for managing internal cellular waste. This interference leads to a rapid buildup of Reactive Oxygen Species (ROS), inducing profound oxidative damage that accelerates cellular degradation. Furthermore, the molecule modulates fungal morphogenesis by preventing the transformation of Candida into its filamentous hyphal form, which results in the structural limitation of the organism’s morphology

How to Use Гино-Дактарин (Miconazole Nitrate) Official Administration Guidelines

Гино-Дактарин is approved for local use only, which includes intravaginal use for the main infection and external vulvar use for the accompanying cream. Proper use requires strict adherence to the administration route, dose, and duration defined for the product.

---

Official Routes and Dosage Schedules

The medication is administered in a specific pattern based on the form and strength, typically once daily at bedtime to ensure retention of the product.

Dosage Form and Strength	Standard Dosing Regimen	Typical Duration
Vaginal Cream (2% or 4% )	One full applicatorful (approx 100 mg or 200 mg)	7 consecutive days (or 3-7 days)
Suppository (200 mg)	One 200 mg suppository, inserted deep	3 consecutive days
Suppository (1200 mg)	One 1200 mg suppository, inserted deep	1 day (Single Dose)
External Cream	Apply small amount to external affected area	Twice daily (as needed, up to 7 days)

---

Administration Requirements and Procedural Rules

Official instructions mandate precise procedural steps to ensure the correct application of the product, regardless of the strength or form used:

• Method of Application: The dose must be inserted deeply into the vagina, generally using the provided applicator, and should be administered at bedtime for optimal efficacy.
• Course Completion: Treatment must be continued for the full course as prescribed, even if symptoms disappear or the menstrual cycle begins.
• Concurrent Product Use: Patients are specifically instructed to not use tampons, douches, spermicides, or other vaginal products concurrently, as these may interfere with the drug's intended action or damage latex contraceptives.
• Partner Use: The 2% cream may be applied to the glans penis of the male sexual partner twice daily for the same treatment duration.

Research Evidence / Overview of Studies for Гино-Дактарин

Evidence for Use in Vulvovaginal Candidiasis

The clinical evaluation of Miconazole Nitrate relies primarily on randomized controlled trials (RCTs) that examined groups of adult women with microbiologically confirmed fungal infections. Researchers monitored several therapeutic outcomes, including the Mycological Cure Rate (the laboratory measure for fungal clearance) and the Clinical Cure Rate, which tracks the collected data on symptom resolution. Studies reported measurements related to the Mycological Cure Rate across different treatment courses. Research has also explored patient-reported outcomes describing perceived discomfort and the Time to Symptom Relief in comparative trials evaluating different regimens (e.g., single-day versus multi-day courses). Follow-up durations in these studies were often limited, and the long-term durability and differences in symptomatic recurrence rates between the various courses are not fully established.

Evidence Gaps and Specific Populations

The main body of robust data is derived from studies involving generally healthy immunocompetent adult women. However, evidence has also been gathered for specific populations, such as diabetic patients, allowing researchers to check if patterns in cure rates differed in this subgroup. The product was also evaluated in adolescents (aged 12 and older). Data for other groups, such as pregnant patients, rely on less extensive post-marketing or observational follow-up reports, and the evidence quality varies across these smaller subgroups.

A key limitation in the research is the narrow focus on Candida albicans, meaning that data for less common, non-albicans species remains less comprehensive. Overall, while research provides insight into short-term changes and acute symptom management, long-term effects are not fully established for all aspects of the condition.

Key Studies & References

1. Miconazole Vaginal: MedlinePlus Drug Information

Common questions about Гино-Дактарин (FAQ)

Q: What makes Gyno-Daktarin different from other vaginal treatments?

A: Official regulatory documents define Gyno-Daktarin as an Azole antifungal containing Miconazole Nitrate. This active ingredient works specifically by preventing the synthesis of ergosterol, which is essential for the fungal cell structure, and this is how its action is defined in pharmacological descriptions.

Q: How long does it usually take for Gyno-Daktarin to start providing relief?

A: Clinical studies track the 'Time to Symptom Relief' as an indicator of efficacy. Official data suggests that patients may notice improvement in symptoms within the first few days of treatment. Regulatory administration guidelines mandate that the full prescribed course must be completed, even if symptoms improve quickly.

Q: Does Gyno-Daktarin treat bacterial infections, or only fungal infections?

A: Gyno-Daktarin is approved for treating local infections caused only by fungi susceptible to miconazole nitrate, specifically vulvovaginal candidiasis. Due to its mechanism of action—targeting fungal cell structures—it is not indicated for the treatment of bacterial infections.

Q: What do official sources say about the possibility of infection recurrence after using Gyno-Daktarin?

A: Studies primarily tracked short-term changes and acute symptom management. Official regulatory reviews acknowledge that the long-term durability of the treatment and differences in recurrence rates between various courses are not fully established based on the existing body of evidence.

Q: Is any special preparation needed before using Gyno-Daktarin suppositories?

A: Official instructions require that users thoroughly wash their hands before and after applying the suppository or cream. The instructions also state the medication should be inserted deeply into the vagina, preferably at bedtime, to ensure optimal retention and efficacy.

Q: What is the frequency of allergic reactions to Gyno-Daktarin?

A: Reactions such as hypersensitivity (including anaphylactic reaction) are classified in official documents as having an Unknown Frequency (Frequency Not Known). This classification indicates that the rate of occurrence cannot be accurately estimated from the available data reported to regulatory bodies.

Q: Is there a difference in effectiveness between the Gyno-Daktarin suppository and cream forms?

A: The active ingredient, miconazole nitrate, is the same across all approved forms. Clinical studies evaluated the effectiveness of various regimens, and all approved forms are included within the established indications for treating vulvovaginal candidiasis.

Q: Is there information about Gyno-Daktarin interacting with herbs or supplements?

A: Official documents prioritize reporting interactions with other licensed medicinal products, such as anticoagulants and oral contraceptives. The regulatory summary does not contain specific, documented information about the interaction of Gyno-Daktarin with herbal products or dietary supplements.

Q: What are the signs that Gyno-Daktarin may not be suitable for a patient?

A: Official documentation indicates that the medicine is strictly contraindicated if a known hypersensitivity to miconazole nitrate or other azole antifungals exists. Documented serious reactions include hypersensitivity reactions, such as anaphylactic reaction or angioedema.

Q: What is the reason for the difference in recommended Gyno-Daktarin treatment courses?

A: The different durations of treatment courses (e.g., 1, 3, or 7 days) are directly related to variations in the dosage and specific formulation of the medicine (cream or suppository). These specific regimens have been evaluated and approved by regulatory authorities.

Q: Is Gyno-Daktarin considered an over-the-counter (OTC) medicine?

A: Official legal classification indicates that Gyno-Daktarin is typically a prescription-only medicine (Rx) in most jurisdictions worldwide. The exact prescription status, however, may vary depending on the local regulations of each country.

Q: What do official instructions say about missing one dose of Gyno-Daktarin?

A: Official guidelines state that a missed dose should usually be taken as soon as it is remembered. The guidance also specifies that the dose should not be doubled to compensate for a missed dose, ensuring the full treatment duration is respected.

Q: Is it possible for Gyno-Daktarin to interact with alcohol?

A: Because the systemic absorption of miconazole nitrate from the vaginal form is minimal, official regulatory documents contain no reported data on a clinically significant interaction between Gyno-Daktarin and alcohol consumption.

Q: Are there any restrictions on physical activity during Gyno-Daktarin treatment?

A: Official instructions focus on ensuring product retention, prescribing deep insertion, preferably before sleep. There are no explicit constraints on normal physical activity in the official labeling, though the use of tampons and other vaginal products is restricted.

Q: Does Gyno-Daktarin affect the results of laboratory tests?

A: Official documents indicate that Gyno-Daktarin may affect the International Normalized Ratio (INR), a common lab test, in patients taking oral anticoagulants. This is due to a potential drug interference documented in regulatory sources.

Q: What should be done if symptoms do not improve after using Gyno-Daktarin?

A: Official regulatory instructions contain guidance that if symptoms persist after completing the full course of treatment, medical advice should be sought. This is recommended to allow for the re-evaluation of the original diagnosis.

Q: How is Gyno-Daktarin described concerning safety for drivers?

A: Official documents, such as the Summary of Product Characteristics (SmPC), indicate that Gyno-Daktarin has no or minimal influence on the ability to drive and operate machinery. This is attributed to the drug's minimal systemic absorption following topical vaginal application.

Q: What do official sources say about accidental ingestion or overdose of Gyno-Daktarin?

A: In the case of accidental ingestion of a large amount of the medicine, official overdose information advises that medical attention should be sought immediately. Reported symptoms of overdose from high oral exposure may include nausea and vomiting.

Q: Is Gyno-Daktarin included in the list of essential medicines?

A: Miconazole, the active ingredient in Gyno-Daktarin, is recognized internationally as an important medicine. It is included in the World Health Organization's Essential Medicines List (EML) as an antifungal medicine.

Q: How long does Gyno-Daktarin remain in the body?

A: The systemic absorption of miconazole nitrate after vaginal administration is very low. Official pharmacokinetic properties indicate that the half-life—the time required for the concentration to halve—is approximately 24 hours.

How to Store and Dispose of Gyno-Daktarin (Miconazole Nitrate)

The storage and disposal of Gyno-Daktarin must adhere strictly to official regulatory guidelines to maintain product integrity and safety.

Official Storage Requirements

Storage Parameter	Regulatory Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C. Do not store above 30 C.
Protection	The medicine must be protected from light and moisture. Do not freeze the product.
Safety	Keep Gyno-Daktarin out of the sight and reach of children.
Container	The medicine must be kept in its original packaging until the time of use.

Disposal Instructions

Do not dispose of unused or expired Gyno-Daktarin in household rubbish or by flushing it into wastewater (sinks or toilets). The medicine must be returned to a pharmacy or an authorized collection facility for proper disposal in line with local pharmaceutical waste regulations. Do not use the product after the expiration date printed on the packaging.